SCHEMBL263146

SCHEMBL263146

COC(=O)c1ccc2cc(C(C)(OC)C(F)(F)F)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.54
CYP17A1 P05093 1/20 0.46
CYP3A4 P08684 1/20 0.46
PDK1 Q15118 2/20 0.46
PDK2 Q15119 2/20 0.46
PDK3 Q15120 2/20 0.46
PDK4 Q16654 2/20 0.46
NOTUM Q6P988 2/20 0.44
LCK P06239 1/20 0.44
KDM4E B2RXH2 3/20 0.43
PLAU P00749 1/20 0.43
LMNA P02545 2/20 0.42
CYP19A1 P11511 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263986 0.87 PTPN1 (0.55) PTPN11PDK1PDK2PDK3PDK4
SCHEMBL269137 0.86 PTPN1 (0.40) PTPN11CYP17A1CYP3A4KDM4EPLAU
SCHEMBL264109 0.84 CYP17A1 (0.50) PTPN11CYP17A1CYP3A4PDK1PDK2
SCHEMBL284015 0.83 ALDH1A1 (0.40) PTPN11KDM4ELMNAALDH1A1RAB9A
SCHEMBL19554198 0.83 NOTUM (0.54) PTPN11CYP17A1CYP3A4NOTUMLCK
SCHEMBL263634 0.82 KIF11 (0.57) PTPN11CYP17A1CYP3A4LCKLMNA
SCHEMBL14378327 0.79 PTPN11 (0.49) PTPN11CYP17A1CYP3A4NOTUMLCK
SCHEMBL10751302 0.78 PTPN11 (0.50) PTPN11CYP17A1CYP3A4LCKKDM4E
SCHEMBL11744372 0.78 PTPN11 (0.50) PTPN11CYP17A1CYP3A4NOTUMLCK
SCHEMBL69025 0.78 PTPN11 (0.68) PTPN11LCKKDM4EPLAULMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 US disclosed
EP-2091944-B1 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER (US) 2011-05-18 EP disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
EP-2044018-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS Pfizer Japan, Inc. (JP) 2009-04-08 EP disclosed
WO-2008007211-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 PTPN11 4176/4885CYP17A1 2587/4885CYP3A4 1721/4885
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 PTPN11 3427/4885CYP17A1 2071/4885CYP3A4 916/4885
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 PTPN11 2178/4885CYP17A1 4396/4885CYP3A4 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.